公开(公告)号：US20230203032A1

公开(公告)日：2023-06-29

申请号：US18057505

申请日：2022-11-21

Applicant: Novartis AG

Inventor： Atwood Kim CHEUNG ,  Donglei LIU ,  Stefan PEUKERT ,  Heng GE ,  Yu GAI ,  Xingjuan CHANG

IPC: C07D471/04 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K45/06

Abstract: The invention relates to a compound of formula (I):




or a pharmaceutically acceptable salt thereof, wherein A, R1 and R3 are as described herein, as well as compositions and methods of using such compounds.

公开(公告)号：US20220324811A1

公开(公告)日：2022-10-13

申请号：US17656313

申请日：2022-03-24

Applicant: Novartis AG

Inventor： Donglei LIU ,  Julien PAPILLON ,  Stefan PEUKERT ,  James J. POWERS

IPC: C07D217/02 ,  C07D401/12 ,  C07D417/12 ,  C07D405/12

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.

公开(公告)号：US20240391941A1

公开(公告)日：2024-11-28

申请号：US18670859

申请日：2024-05-22

Applicant: Novartis AG

Inventor： Atwood CHEUNG ,  Donglei LIU ,  Stefan PEUKERT ,  John TRAUGER

IPC: C07F9/6561 ,  A61K31/4375 ,  A61K45/06 ,  C07D471/04

Abstract: The present disclosure relates to a compound which is a phosphoric acid ester derivative of a compound of formula (I): wherein A, L and R3 are as described herein, as well as compositions and methods of using such compound.